| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5617 | 2014 |
| Review of 1027 patients with newly diagnosed multiple myeloma RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy, A Dispenzieri, ... Mayo clinic proceedings 78 (1), 21-33, 2003 | 3466 | 2003 |
| Improved survival in multiple myeloma and the impact of novel therapies SK Kumar, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, ... Blood, The Journal of the American Society of Hematology 111 (5), 2516-2520, 2008 | 2886 | 2008 |
| Nonbiopsy diagnosis of cardiac transthyretin amyloidosis JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ... Circulation 133 (24), 2404-2412, 2016 | 1920 | 2016 |
| Prevalence of monoclonal gammopathy of undetermined significance RA Kyle, TM Therneau, SV Rajkumar, DR Larson, MF Plevak, JR Offord, ... New England Journal of Medicine 354 (13), 1362-1369, 2006 | 1759 | 2006 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1595 | 2014 |
| Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study O Landgren, RA Kyle, RM Pfeiffer, JA Katzmann, NE Caporaso, RB Hayes, ... Blood, The Journal of the American Society of Hematology 113 (22), 5412-5417, 2009 | 1499 | 2009 |
| POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. A Dispenzieri, RA Kyle, MQ Lacy, SV Rajkumar, TM Therneau, DR Larson, ... Blood, The Journal of the American Society of Hematology 101 (7), 2496-2506, 2003 | 1255 | 2003 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1251 | 2007 |
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ... Journal of Clinical Oncology 30 (9), 989-995, 2012 | 1199 | 2012 |
| Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma RA Kyle, ED Remstein, TM Therneau, A Dispenzieri, PJ Kurtin, ... New England Journal of Medicine 356 (25), 2582-2590, 2007 | 1179 | 2007 |
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis A Dispenzieri, MA Gertz, RA Kyle, MQ Lacy, MF Burritt, TM Therneau, ... Journal of clinical oncology 22 (18), 3751-3757, 2004 | 1085 | 2004 |
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hajek, ... Leukemia 23 (2), 215-224, 2009 | 1084 | 2009 |
| Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem … BGM Durie, A Hoering, MH Abidi, SV Rajkumar, J Epstein, SP Kahanic, ... The Lancet 389 (10068), 519-527, 2017 | 1029 | 2017 |
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... Journal of clinical oncology 30 (36), 4541-4549, 2012 | 1009 | 2012 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 995 | 2012 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 962 | 2014 |
| Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance SV Rajkumar, RA Kyle, TM Therneau, LJ Melton III, AR Bradwell, RJ Clark, ... Blood 106 (3), 812-817, 2005 | 908 | 2005 |
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma SV Rajkumar, SR Hayman, MQ Lacy, A Dispenzieri, SM Geyer, B Kabat, ... Blood 106 (13), 4050-4053, 2005 | 886 | 2005 |
| Clonal competition with alternating dominance in multiple myeloma JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012 | 818 | 2012 |
